Skip to main content
//empty //empty

Montreal cancer drug developer Repare Therapeutics Inc. increased the size and value of its impending Nasdaq initial public offering for the second time Wednesday, following a slew of well-received biotech IPOs south of the border in recent weeks.

The company said in a filing with the U.S. Securities and Exchange Commission it will now offer 10 million shares at US$18 to US$20 each. Its underwriters – Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler – have the option to buy another 1.5 million shares at that price, which could yield gross proceeds of US$230-million

That’s up from a filing Monday in which Repare said it would offer 7.4 million shares plus 1.1 million for underwriters valued at US$16 to US$18 each. Repare revealed plans on May 29 to raise US$100-million.

Story continues below advertisement

In the past week, two California biotech developers, Vaxcyte Inc. and Avidity Biosciences LLC, saw their stocks pop by 50 per cent or more on their first day of trading. Several other stocks of drug developers have doubled in value since going public this year. If Repare follows in that path, it could be the latest in a string of Canadian biotechs to achieve US$1-billion valuations in the past two years.

This has been a strong year for biotech, beyond heightened interest in companies developing COVID-19 treatments, as stocks of many drug developers spiked after their IPOs. Another Canadian cancer treatment developer, Hamilton-based Fusion Pharmaceuticals is also in the process of going public on Nasdaq, while Chinook Therapeutics Inc., a kidney-disease drug developer jointly based in Vancouver and Seattle, said it would merge with Nasdaq-traded Aduro Biotech Inc. They follow three other Canadian biotech companies that went public or cross-listed on Nasdaq last year.

Repare is developing “precision oncology” drugs that attack genetic defects in cancerous tumors, preventing toxic cells from repairing their DNA. Repare aims to get its lead drug candidate into human trials this summer. In May, it struck a partnership with Bristol Myers Squibb to identify drug candidates.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today

Follow related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies